Davidson Investment Advisors increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 326,333 shares of the biopharmaceutical company’s stock after purchasing an additional 72,016 shares during the quarter. Gilead Sciences accounts for 2.9% of Davidson Investment Advisors’ investment portfolio, making the stock its 6th biggest holding. Davidson Investment Advisors’ holdings in Gilead Sciences were worth $26,439,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in the business. Arvest Bank Trust Division grew its position in shares of Gilead Sciences by 1.1% in the second quarter. Arvest Bank Trust Division now owns 238,542 shares of the biopharmaceutical company’s stock valued at $16,884,000 after purchasing an additional 2,665 shares during the period. Union Bankshares Corp boosted its holdings in Gilead Sciences by 4.4% in the second quarter. Union Bankshares Corp now owns 6,234 shares of the biopharmaceutical company’s stock valued at $441,000 after acquiring an additional 260 shares during the last quarter. Kempner Capital Management Inc. boosted its holdings in Gilead Sciences by 3.8% in the second quarter. Kempner Capital Management Inc. now owns 66,890 shares of the biopharmaceutical company’s stock valued at $4,734,000 after acquiring an additional 2,428 shares during the last quarter. Swedbank boosted its holdings in Gilead Sciences by 0.4% in the second quarter. Swedbank now owns 2,214,959 shares of the biopharmaceutical company’s stock valued at $156,775,000 after acquiring an additional 9,857 shares during the last quarter. Finally, NEXT Financial Group Inc boosted its holdings in Gilead Sciences by 74.2% in the second quarter. NEXT Financial Group Inc now owns 16,600 shares of the biopharmaceutical company’s stock valued at $1,175,000 after acquiring an additional 7,072 shares during the last quarter. 76.47% of the stock is owned by institutional investors.
A number of research analysts have commented on the company. Mizuho set a $95.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, February 5th. Leerink Swann cut their price target on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Bank of America boosted their price target on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Morgan Stanley lowered their price objective on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. Finally, Credit Suisse Group set a $80.00 price objective on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $87.04.
Gilead Sciences, Inc. (GILD) traded up $1.03 during midday trading on Wednesday, hitting $81.82. 7,060,000 shares of the stock were exchanged, compared to its average volume of 10,070,000. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48. The firm has a market capitalization of $106,850.00, a P/E ratio of 23.51, a PEG ratio of -1.83 and a beta of 1.22. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the prior year, the business posted $2.70 earnings per share. The business’s quarterly revenue was down 18.7% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 6.24 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is 59.77%.
In related news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the sale, the insider now owns 3,070,099 shares in the company, valued at $230,196,023.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gayle E. Wilson sold 60,000 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the sale, the director now owns 182,258 shares of the company’s stock, valued at approximately $14,201,543.36. The disclosure for this sale can be found here. Insiders have sold 418,333 shares of company stock valued at $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Shares Bought by Davidson Investment Advisors” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/15/gilead-sciences-inc-gild-shares-bought-by-davidson-investment-advisors-3.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.